Healx, a U.K. startup using AI to discover new drugs for rare diseases, has raised $47 million in a Series C round of funding co-led by Europe's Atomico and Silicon Valley-based R42.

Healx, a leading AI-driven drug discovery company focused on rare diseases, announces Christopher Moertel, M.D., as Global Head of Clinical Development We are thrilled to welcome Dr. Moertel to ...

CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease ...

CAMBRIDGE, England, February 24, 2025--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company dedicated to rare diseases, today announced the first patient has been dosed in INSPIRE ...

In conjunction with the financing, Stanford Medicine Adjunct Professor Ronjon Nag, Ph.D., founder of R42 Group and 2024 Silicon Valley Hall of Fame AI inductee, joins the board of Healx.

The lab will allow the Healx team to accelerate the discovery of potential new therapies for more rare conditions The lab will allow the Healx team to accelerate the discovery of potential new ...

Global pharmaceutical company Sanofi is partnering with Healx, a U.K.-based clinical-stage biotech specializing in rare diseases, to use its artificial intelligence to identify novel rare disease ...

Healx has raised $47 million in a Series C round co-led by Silicon Valley-based R42 Group and Atomico with participation from new and existing investors including Balderton, Jonathan Milner ...